There have been no reported cases of encapsulated meningococcal infections in any adults with PNH treated with pegcetacoplan, as of 11/13/2025
Ingredients Tridecyl Trimellitate, Octyldodecanol, Dipentaerythritol Hexahydroxystearate/Hexastearate/Hexarosinate, Diisostearyl Malate, Caprylic/Capric Triglyceride, Polyisobutene, Polyglyceryl-3 Triisostearate, Synthetic Wax, Synthetic Beeswax, Microcrystalline Wax, Ricinus Communis (Castor) Seed Oil, Ethylene/Propylene/Styrene Copolymer, Polyglyceryl-2 Isostearate, 1,2-Hexanediol, Lavandula Angustifolia (Lavender) Oil, Yellow 6 Lake (CI 15985), Titanium Dioxide (CI 77891), Glycol, Red 7 Lake (CI 15850), Linalool, Yellow 5 Lake (CI 19140), Ethylhexylglycerin, Pentaerythrityl Tetra-di-t-butyl Hydroxyhydrocinnamate, Red 6 (CI 15850), Red 27 (CI 45410), Geraniol, Butyrospermum Parkii (Shea Butter), Shorea Robusta Seed Butter, Glutathione Content 9 g / 0.26 oz For Topical and Cosmetic Use Only
Use separate GHRHR and GHSR-1a potency assays
In the one published human clinical study of CJC-1295 with DAC a Phase I dose-escalation trial in healthy adults tolerability was characterized as good, with injection-site reactions reported as the most common adverse effect
In certain animal studies, its been found that IGF-1 may help protect against Parkinsons disease and induce clearance of brain amyloid-betas, which at high levels are associated with Alzheimers disease
